While semaglutide is the underlying drug, regulators, manufacturers, insurers, and pharmacies each interact with it differently
Your provider can review your BMI, health history, medications, weight loss goals, prior treatment experience, side effects, and budget to help determine which GLP-1 or GLP-1/GIP option may be appropriate
The PIONEER-6 trial suggests cardiovascular benefit of oral semaglutide in patients with diabetes compared to placebo
PMID 33297945
Customizable Treatment Plans: The use of empagliflozin in combination therapy allows healthcare providers to customize treatment plans for each patient, considering factors like the extent of blood sugar control required, patient tolerance to medications, and the presence of other health conditions